An official website of the United States government
Here's how you know
A .mil website belongs to an official U.S. Department of Defense organization in the United States.
A lock (lock ) or https:// means you’ve safely connected to the .mil website. Share sensitive information only on official, secure websites.

Text/HTML

 
 
 
 
 
 
 
 
 
 

HotInfo

ImageGallery

BETHESDA, Md. (May 10, 2024) Hospital Corpsman 1st Class Adirachel Sauvou, from Naval Medical Research Command (NMRC), draws a blood samples as part of training for a flu prevention study. The study, an ongoing trial conducted by the NMRC Clinical Trials Center (CTC), evaluates the efficacy of SAb Biotherapeutics therapy SAB-176, a novel infectious disease therapy designated by the U.S. Food and Drug Administration. According to the Centers for Disease Control and Prevention, more than 14,000,000 medical visits, 360,000 hospitalizations and 21,000 deaths occurred in the United States due to influenza from 2022-2023. Influenza outbreaks can spread easily among active-duty service members, especially those living in congregate settings, reducing mission readiness. A prevention option that can be administered remotely could reduce disease burden and optimize health and operational readiness of Navy, Marine Corps and joint service personnel in all domains that may face a rapidly transmitted infectious disease threat.

This study is open to all healthy active-duty military, dependents, retirees, WRNMMC personnel and other local individuals between the ages of 18 and 60. Participants must not be pregnant, cannot have received a flu shot in the past 90 days and must be able to complete at least eight visits to the CTC over the course of three months. Active-duty personnel will be required to complete a supervisor’s approval form. Participants may be eligible for compensation. If you would like to participate or have any questions, please contact the center at 301-233-9640 (text), or via e-mail at usn.nmrc.ctc@health.mil to schedule an appointment. The CTC, located at Naval Support Activity Bethesda, Building 17B (2nd floor), evaluates vaccines, therapeutics, prophylactics and medical devices in human subjects to advance products from the laboratory to the front line and maximize the medical readiness of the warfighter. (U.S. Navy photo by Sidney Hinds/Released)
240510-N-KT630-1144.JPG Photo By: Sidney Hinds

May 31, 2024
BETHESDA, MD - BETHESDA, Md. (May 10, 2024) Hospital Corpsman 1st Class Adirachel Sauvou, from Naval Medical Research Command (NMRC), draws a blood samples as part of training for a flu prevention study. The study, an ongoing trial conducted by the NMRC Clinical Trials Center (CTC), evaluates the efficacy of SAb Biotherapeutics therapy SAB-176, a novel infectious disease therapy designated by the U.S. Food and Drug Administration. According to the Centers for Disease Control and Prevention, more than 14,000,000 medical visits, 360,000 hospitalizations and 21,000 deaths occurred in the United States due to influenza from 2022-2023. Influenza outbreaks can spread easily among active-duty service members, especially those living in congregate settings, reducing mission readiness. A prevention option that can be administered remotely could reduce disease burden and optimize health and operational readiness of Navy, Marine Corps and joint service personnel in all domains that may face a rapidly transmitted infectious disease threat. This study is open to all healthy active-duty military, dependents, retirees, WRNMMC personnel and other local individuals between the ages of 18 and 60. Participants must not be pregnant, cannot have received a flu shot in the past 90 days and must be able to complete at least eight visits to the CTC over the course of three months. Active-duty personnel will be required to complete a supervisor’s approval form. Participants may be eligible for compensation. If you would like to participate or have any questions, please contact the center at 301-233-9640 (text), or via e-mail at usn.nmrc.ctc@health.mil to schedule an appointment. The CTC, located at Naval Support Activity Bethesda, Building 17B (2nd floor), evaluates vaccines, therapeutics, prophylactics and medical devices in human subjects to advance products from the laboratory to the front line and maximize the medical readiness of the warfighter. (U.S. Navy photo by Sidney Hinds/Released)


DOWNLOAD PHOTO (4.02 MB)


This photograph is considered public domain and has been cleared for release. If you would like to republish please give the photographer appropriate credit. Further, any commercial or non-commercial use of this photograph or any other DoD image must be made in compliance with guidance found at http://www.dimoc.mil/resources/limitations.html , which pertains to intellectual property restrictions (e.g., copyright and trademark, including the use of official emblems, insignia, names and slogans), warnings regarding use of images of identifiable personnel, appearance of endorsement, and related matters.



Back to Gallery

SiteWideFooter- glc


Guidance-Card-Icon Dept-Exclusive-Card-Icon